Table 1.
Baseline characteristics of patients who completed the study
| Switch to the highest dose of rosuvastatin | Add-on-statin ER-NA/LRPT | Add-on-statin micronised fenofibrate | P | |
| Sex (males/females) | 32 (17/15) | 26 (14/12) | 32 (16/16) | NS |
| Age (yr) | 62 ± 10 | 58 ± 14 | 59 ± 12 | NS |
| Hypertension | 17 (53) | 14 (54) | 16 (50) | NS |
| Diabetes mellitus | 6 (19) | 6 (23) | 6 (19) | NS |
| Metabolic syndrome1 | 17 (53) | 15 (58) | 18 (56) | NS |
| Smoking | 10 (31) | 9 (35) | 9 (28) | NS |
| BMI (kg/m2) | 29.1 ± 2.5 | 29.1 ± 3.1 | 28.8 ± 3.2 | NS |
| TC | NS | |||
| (mg/dL) | 205 ± 40 | 200 ± 42 | 200 ± 37 | |
| (mmol/L) | 5.5 ± 1 | 5.2 ± 1.1 | 5.2 ± 1 | |
| Triglycerides | NS | |||
| (mg/dL) | 190 (173-210) | 213 (190-254) | 218 (189-260) | |
| (mmol/L) | 2.2 (2.0-2.4) | 2.4 (2.2-2.9) | 2.5 (2.1-2.9) | |
| HDL-C | NS | |||
| (mg/dL) | 50 ± 10 | 47 ± 11 | 45 ± 9 | |
| (mmol/L) | 1.3 ± 0.3 | 1.2 ± 0.3 | 1.1 ± 0.2 | |
| LDL-C | NS | |||
| (mg/dL) | 116 ± 40 | 109 ± 35 | 112 ± 32 | |
| (mmol/L) | 3.2 ± 1.0 | 2.9 ± 0.9 | 2.9 ± 0.8 | |
| Non-HDL-C | NS | |||
| (mg/dL) | 155 ± 40 | 153 ± 37 | 155 ± 34 | |
| (mmol/L) | 4.0 ± 1.0 | 4.0 ± 1.0 | 4.0 ± 0.9 | |
| Fasting plasma glucose | NS | |||
| (mg/dL) | 91 ± 26 | 93 ± 17 | 94 ± 10 | |
| (mmol/L) | 5.1 ± 1.4 | 5.2 ± 0.9 | 5.2 ± 0.6 | |
| HbA1c (%) | 6.1 ± 0.5 | 6.3 ± 1.1 | 6.1 ± 0.8 | NS |
| HOMA-IR index | 1.4 1.2-2.1 | 1.5 1.4-2.1 | 1.7 1.5-2.3 | NS |
| Medications at baseline | ||||
| Aspirin | 9 (28) | 8 (31) | 7 (22) | NS |
| Beta blockers | 9 (28) | 8 (31) | 9 (28) | NS |
| HCTZ | 11 (34) | 10 (38) | 10 (31) | NS |
| ACEIs/ARBs | 13 (41) | 11 (42) | 12 (38) | NS |
| Calcium channel blockers | 8 (24) | 8 (31) | 10 (31) | NS |
| Metformin | 6 (19) | 6 (23) | 5 (16) | NS |
| Pioglitazone | 2 (7) | 1 (4) | 3 (9) | NS |
| Sulfonylurea | 4 (13) | 3 (12) | 2 (6) | NS |
| Atorvastatin 5-20 mg/d | 11 (34) | 9 (35) | 12 (38) | NS |
| Simvastatin 10-40 mg/d | 11 (34) | 9 (35) | 9 (28) | NS |
| Rosuvastatin 5-10 mg/d | 10 (31) | 8 (31) | 11 (34) | NS |
Values are expressed as absolute mean ± SD [except for triglycerides and HOMA-IR index which are expressed as median (range)] or numbers (percentage).
Participants who fulfilled 3 or more of the American Heart Association (AHA) criteria for the diagnosis of metabolic syndrome (waist circumference > 102 cm in men, > 88 cm in women, fasting serum triglycerides > 150 mg/dL, HDL-C < 40 mg/dL in men, < 50 mg/dL in women, blood pressure > 130/85 mm Hg, fasting serum glucose > 100 mg/dL). ACEIs: Angiotensin converting enzyme inhibitors; ApoB: Apolipoprotein B; ARBs: Angiotensin receptor blockers; BMI: Body mass index; ER-NA/LRPT: Extended release nicotinic acid/laropiprant; HCTZ: Hydrochlorothiazide; HDL-C: High-density lipoprotein cholesterol; HbA1c: Glycosylated hemoglobin; HOMA-IR IR index: Homeostasis model assessment of insulin resistance index; NS: Non significant; TC: Total cholesterol.